Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 4Lymphoma, B-Cell 3Lymphoma 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Hematologic Neoplasms 1Disease Progression 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 72fludarabine 65Tacrolimus 43fludarabine phosphate 40Whole-Body Irradiation 37Mycophenolic Acid 35Busulfan 32Melphalan 28Antilymphocyte Serum 23thymoglobulin 22Thiotepa 20Methotrexate 20Standard of Care 19Stem Cell Transplantation 17Practice Guidelines as Topic 17Granulocyte Colony-Stimulating Factor 17Rituximab 15Surveys and Questionnaires 12Sirolimus 12Filgrastim 12Interviews as Topic 11Cyclosporine 11Blood Specimen Collection 11Peripheral Blood Stem Cell Transplantation 10Exercise 10venetoclax 9Mesna 9Cytarabine 9Bortezomib 9Hematopoietic Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Neoplasms × axicabtagene ciloleucel × Clear all
NCT04432506 2025-01-28

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
22 enrolled 15 charts
LymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡